Diligence memo · auto-generated · as of July 2, 2026
Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Sensei Biotherapeutics, Inc. operates in Biotechnology, based in ROCKVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Sensei Biotherapeutics, Inc. has raised $349M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $349M on 2026-02-17.
Most recent recorded round closed around 2026-02-17.
Valuation (modeled)modeled
Provath models Sensei Biotherapeutics, Inc. at approximately $2.2B (range $1.6B–$2.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.53× the median modeled value of Series D+ Biotechnology companies in 2025–2027 (33 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 4 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 99% of Biotechnology peers (4293 compared).
Modeled value ranks above 95% of those peers.
Closest niche peers: Kriya Therapeutics, Inc., Pathos AI, Inc., Odyssey Therapeutics, Inc., Rhodenergy An Environmental Co Corp, Tectonic Therapeutic, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.